Overview

Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma

Status:
Active, not recruiting
Trial end date:
2022-05-24
Target enrollment:
Participant gender:
Summary
Primary Objective: To evaluate the efficacy of dupilumab in patients with persistent asthma Secondary Objectives: - To evaluate the safety and tolerability of dupilumab - To evaluate the effect of dupilumab on improving patient reported outcomes including health related quality of life - To evaluate dupilumab systemic exposure and immunogenicity
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Antibodies, Monoclonal
Prednisolone
Prednisone